Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Genomic, Transcriptomic Profiling Lays Groundwork for Personalization in RCC

Caroline Seymour
Published: Tuesday, Jan 29, 2019

A. Ari Hakimi, MD

A. Ari Hakimi, MD

RNA-based analyses of prospectively-collected tumor specimens from patients with metastatic renal cell carcinoma (mRCC) in the phase III COMPARZ trial revealed 4 molecular subgroups, of which a high angiogenesis expression and a low macrophage infiltrate were indicative of response to frontline TKI therapy.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication